Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Vioxx Hearing May Be Sign Of Things To Come Under Medicare Rx

Executive Summary

The Senate Finance Committee should continue to review FDA's drug safety procedures in light of the upcoming expansion of the Medicare program, Ranking Democrat Max Baucus (D-Mont.) maintained during the committee's Nov. 18 hearing on Vioxx

You may also be interested in...



Senate Health Committee Adds Republican Sens. Burr, Hatch

Sen.-elect Richard Burr (R-N.C.) will bring a long history of involvement in prescription drug issues to the Senate Health Committee in the 109th Congress

Senate Health Committee Adds Republican Sens. Burr, Hatch

Sen.-elect Richard Burr (R-N.C.) will bring a long history of involvement in prescription drug issues to the Senate Health Committee in the 109th Congress

Senate Health Cmte. Drug Safety Focus Will Be Antidepressants, Not Vioxx

The Senate Health Committee's oversight of FDA's drug safety regulation is likely to focus on the agency's handling of antidepressants

Related Content

Topics

UsernamePublicRestriction

Register

PS045047

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel